Discovery (observation)

Kat Cooper shares her triumphant story of faith and God's victory in 'Unconquered Heart'

Retrieved on: 
Mardi, octobre 24, 2023
Courage, Discovery (observation), Thomas Nelson (publisher), Love, Catholic Church, Lord, Trauma, Parent, Life, Baking

LAKEWOOD RANCH, Fla., Oct. 24, 2023 /PRNewswire-PRWeb/ -- New release "Unconquered Heart: Overcoming Extraordinary Adversity and Discovering Your True Purpose Through Faith" (published by WestBow Press) is a true-life testimony of God's victory over three generations of trauma and abuse.

Key Points: 
  • In this book, Kat Cooper shares her experiences growing up in a dysfunctional home with both parents having been horribly abused as children.
  • The effects of her childhood sent Cooper in search of God and his purpose for her life.
  • She chronicles her 20-year journey and her ultimate decision to be baptized at age 40 years old in the Catholic faith.
  • Her story is a hopeful reminder that a new life of joy, peace, purpose and meaning is just a prayer away.

New season of documentary reveals more Hainan nature mysteries

Retrieved on: 
Vendredi, octobre 13, 2023
Language, Slaty-backed forktail, Multimedia, Eld, Leopard gecko, Discovery (observation), Narration, Season, Biodiversity, Love, Nanguo Metropolis Daily, Reproduction, Habit, Rainforest, Film industry, Hunting

The fourth season of the acclaimed nature documentary miniseries This is Hainan: Discovering Mysteries — depicting the secrets of rainforest life in south China's Hainan province — officially premiered on October 13.

Key Points: 
  • The fourth season of the acclaimed nature documentary miniseries This is Hainan: Discovering Mysteries — depicting the secrets of rainforest life in south China's Hainan province — officially premiered on October 13.
  • Since beginning work on the first season in May, 2020, the Discovering Mysteries film crew has traipsed deep into the wilds of Yinggeling, Bawangling, Jianfengling, and other areas of the Hainan Tropical Rainforest National Park.
  • "Ecological and environmental protection are common values of humanity as well as an important area for international dialogue."
  • Jointly produced by the New Hainan App, Hinews, Nanguo Metropolis Daily, and the Hainan International Media Center, the first three seasons of the miniseries have received a total of over 180 million views on both domestic and international media platforms.

Pulse Oil Corp. Announces Significant EOR Progress

Retrieved on: 
Lundi, octobre 31, 2022
ECR, Legislation, Petroleum, Time, SEDAR, Natural gas, Discovery (observation), Disclosure, SEC, P50, Company, Intention, National instrument, Technology, News, Probability, P90, Oil reserves, Oil, Risk management, Uranium, Pulse

In this news release, such statements include but are not limited to Pulses operations and oil and gas resources.

Key Points: 
  • In this news release, such statements include but are not limited to Pulses operations and oil and gas resources.
  • This forward-looking information reflects Pulses current beliefs and is based on information currently available to Pulse and on assumptions Pulse believes are reasonable.
  • These assumptions include, but are not limited to, conditions facing Pulse at the time of the planned expenditure in advancing the Bigoray EOR project, conducting operations on time and on budget and the anticipated reserves, resources, production, revenue and cash flow anticipated from these operations.
  • The forward-looking information contained in this news release represents the expectations of Pulse as of the date of this news release and, accordingly, is subject to change after such date.

Tunnel to Towers Foundation Announces New Tunnel to Towers 9/11 Institute™

Retrieved on: 
Mercredi, septembre 7, 2022
Discovery (observation), Program, Russell, Survivor, Veteran, NEVER, Artifact, Student, Foundation, FDNY, GLOBE, Instagram, Twitter, GOOD, Institute, Tunnel, Facebook

Tunnel to Towers is also proud to announce that it will grant financial scholarships to the children of program recipients who are exemplary high school students preparing for college.

Key Points: 
  • Tunnel to Towers is also proud to announce that it will grant financial scholarships to the children of program recipients who are exemplary high school students preparing for college.
  • That is unacceptable, and we are going to change that moving forward, said Tunnel to Towers Chairman and CEO Frank Siller.
  • The Tunnel to Towers Foundation is dedicated to honoring the sacrifice of FDNY Firefighter Stephen Siller, who laid down his life to save others on September 11, 2001.
  • For more about the Tunnel to Towers Foundation and its commitment to DO GOOD, please visit T2T.org .

Leading health app launches podcast, Discovering Nutrition with Cronometer

Retrieved on: 
Lundi, juillet 25, 2022
Spotify, Podcasts (software), Google Play, Amazon Music, Health, App Store (iOS/iPadOS), Multimedia, Discovery (observation), Music, Google Podcasts, Nutrition, Sleep, Hormone, Community manager, Mobile phone, BC

REVELSTOKE, BC, July 25, 2022 /PRNewswire/ - Nutrition tracking app, Cronometer have announced the launch of a podcast called Discovering Nutrition with Cronometer.

Key Points: 
  • REVELSTOKE, BC, July 25, 2022 /PRNewswire/ - Nutrition tracking app, Cronometer have announced the launch of a podcast called Discovering Nutrition with Cronometer.
  • Discovering Nutrition with Cronometer was launched with the first episode on May 26, which features Dr. Gabrielle Lyon discussing the topic of women's health.
  • Anyone looking to better understand their health and nutrition can sign up for a Cronometer account for free on their website , or download the mobile app on the Apple App Store, or Google Play Store.
  • About Cronometer Software Inc.:Cronometeris a free personal health & nutrition tracker with the most accurate and comprehensive nutrition database on the market.

GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

Retrieved on: 
Mercredi, juin 29, 2022
Hemolysis, Discovery (observation), Patient, Sickle cell disease, Research, GLOBE, COVID-19, Blood, United States $1 Coin Act of 1997, Oxygen, Polymerization, GBT, FDA, HBS, Securities Act of 1933, Securities Exchange Act of 1934, Tissue, National Heart, Lung, and Blood Institute, PD, Compliance, Pharmacokinetics, SAN, Anemia, Drug Quality and Security Act, SCD, Center, Sickle, Acute chest syndrome, Goal, PK, Private Securities Litigation Reform Act, Capillary, NASDAQ, Lung, Pharmakon—Danish College of Pharmacy Practice, Adult, Stroke, U.S. Securities and Exchange Commission, End organ damage, Disease, United, Registry, Volatile organic compound, Maintenance, Government, Safety, Centers for Disease Control and Prevention, Pharmaceutical industry, HB, Voxelotor

The study ( NCT05431088 ) is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT601.

Key Points: 
  • The study ( NCT05431088 ) is a randomized, multicenter Phase 2/3 clinical trial evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of GBT601.
  • Based on compelling preclinical and clinical data, we believe GBT601 has the potential to be a best-in-class therapy for patients with sickle cell disease, said Kim Smith-Whitley, M.D., executive vice president and head of research and development of GBT.
  • The initiation of our Phase 2/3 trial is an important milestone in our efforts to bring GBT601 to patients.
  • GBT601 is being studied in a Phase 1 clinical trial and Phase 2 portion of a Phase 2/3 clinical trial.

Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

Retrieved on: 
Mercredi, février 2, 2022
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, News, Safety, Patient, Rehabilitation, TKA, Sports medicine, Food, University, University of Rochester Medical Center, Scripps Research, Korea Disease Control and Prevention Agency, UCSF, Nobel Prize, TRPV1, Elective surgery, Death, Anesthetic, Doctor of Public Health, ERG, Center, Research, URMC, U.S. News & World Report, Medicine, Hospital, Ambulatory Surgery Center Association, Temperature, Capsaicin, Science, Prodrug, Target, Fast track (FDA), Pain, Outpatient surgery, Regulation of tobacco by the U.S. Food and Drug Administration, Nobel Prize in Physiology or Medicine, Therapy, Discovery (observation), Concentric objects, OTC, Mark (given name), Traffic, Pharmaceutical industry, Analgesic, Physiology

Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.

Key Points: 
  • Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.
  • URMC will participate in the vocacapsaicin Phase 3 clinical trials and develop innovative methods to capture vocacapsaicins benefit to patient recovery and rehabilitation.
  • Concentric Analgesics lead product candidate for postsurgical pain is a proprietary first-in-class prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV1 agonist.
  • Concentric Analgesics is a clinical-stage, biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics.

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule

Retrieved on: 
Lundi, décembre 6, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, National, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Data, Cell, Cancer, Risk, Inflammation, Breakthrough therapy, NIH, EFS, Forward-looking statement, Hospital, AML, Carbohydrate, Acute myeloid leukemia, George Washington University School of Medicine & Health Sciences, SEC, National Cancer Institute, Annual report, European Fusion Development Agreement, Alliance for Clinical Trials in Oncology, Cooperative research and development agreement, U.S. Securities and Exchange Commission, Nasdaq, Washington University School of Medicine, Survival, Adult, Discovery (observation), E-selectin, Bone marrow, Principal investigator, NCI, Form 10-K, Multimedia, Food, Chemistry, Pharmaceutical industry, Uproleselan, GlycoMimetics, Inc., Alliance for Clinical Trials in Oncology, UPROLESELAN, GLYCOMIMETICS, INC., ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

The randomized, controlled trial is evaluating the addition of uproleselan, GlycoMimetics investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.

Key Points: 
  • The randomized, controlled trial is evaluating the addition of uproleselan, GlycoMimetics investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.
  • Geoffrey Uy, M.D., Professor of Medicine, Washington University School of Medicine in St. Louis, is the trials Principal Investigator.
  • GlycoMimetics and NCI are collaborating on the development of uproleselan under a Cooperative Research and Development Agreement.
  • Together, the GlycoMimetics- and NCI-sponsored programs will constitute a large dataset of 650 patients with AML.